Drugs / BMS-986259
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04237831 | Feb 2020 → Jul 2021 | kidney failure | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04008992 | Jun 2019 → Jan 2021 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04318093 | Nov 2020 → Jul 2021 | heart failure | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986259 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04008992 ↗ |